The Indian Council of Medical Research (ICMR) has said that Covaxin, the Indian vaccine against COVID-19, has drawn global attention.
The ICMR tweeted, “India’s indigenous vaccine against COVID19 Covaxin-a product of ICMR-Bharat Biotech collaboration, achieves the remarkable feat. Data generated from within India underlines impressive safety and immunogenicity profile of Covaxin and sparks Lancet’s interest in publishing them.”
The ICMR also tweeted, “Encouraging Phase I and Phase II COVAXIN trial results have paved the path for Phase III Clinical Trial in India, which is currently ongoing at 22 sites.”
On Thursday, All India Institute of Medical Sciences (AIIMS) New Delhi had invited volunteers for the Phase III clinical trial of the indigenously developed COVID-19 vaccine Covaxin for which it is one of the sites.
AIIMS advertised for volunteers to enroll for the Phase III clinical trial of indigenously developed COVID-19 vaccine, Covaxin. In an advertisement AIIMS stated “AIIMS, New Delhi is a site for Covaxin Phase III clinical trial. This is a whole-virion inactivated vaccine co-sponsored by Indian Council of Medical Research (ICMR) and Bharat Biotech.”
Dr Sanjay K Rai, from AIIMS Centre for Community Medicine had informed through the advertisement that Phase I/II trials (safety and immunogenicity) have already been completed.